{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T09:02:03Z","timestamp":1772355723057,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>No residual disease (CC 0) following cytoreductive surgery is pivotal for the prognosis of women with advanced stage epithelial ovarian cancer (EOC). Improving CC 0 resection rates without increasing morbidity and no delay in subsequent chemotherapy favors a better outcome in these women. Prerequisites to facilitate this surgical paradigm shift and subsequent ramifications need to be addressed. This quality improvement study assessed 559 women with advanced EOC who had cytoreductive surgery between January 2014 and December 2019 in our tertiary referral centre. Following implementation of the Enhanced Recovery After Surgery (ERAS) pathway and prehabilitation protocols, the surgical management paradigm in advanced EOC patients shifted towards maximal surgical effort cytoreduction in 2016. Surgical outcome parameters before, during, and after this paradigm shift were compared. The primary outcome measure was residual disease (RD). The secondary outcome parameters were postoperative morbidity, operative time (OT), length of stay (LOS) and progression-free-survival (PFS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>R0 resection rate in patients with advanced EOC increased from 57.3% to 74.4% after the paradigm shift in surgical management whilst peri-operative morbidity and delays in adjuvant chemotherapy were unchanged. The mean OT increased from 133\u2009+\u200955 min to 197\u2009+\u200985\u00a0min, and postoperative high dependency\/intensive care unit (HDU\/ICU) admissions increased from 8.1% to 33.1%. The subsequent mean LOS increased from 7.0\u2009+\u20092.6 to 8.4\u2009+\u20094.9 days. The median PFS was 33 months. There was no difference for PFS in the three time frames but a trend towards improvement was observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Improved CC 0 surgical cytoreduction rates without compromising morbidity in advanced EOC is achievable owing to the right conditions. Maximal effort cytoreductive surgery should solely be carried out in high output tertiary referral centres due to the associated substantial prerequisites and ramifications.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-023-01303-1","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T08:02:00Z","timestamp":1699689720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prerequisites to improve surgical cytoreduction in FIGO stage III\/IV epithelial ovarian cancer and subsequent clinical ramifications"],"prefix":"10.1186","volume":"16","author":[{"given":"Diederick","family":"de Jong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amudha","family":"Thangavelu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Broadhead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dermot","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Racheal","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lodge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Quyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Theophilou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Laios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"key":"1303_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","volume":"53","author":"A Jemal","year":"2003","unstructured":"Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5\u201326. https:\/\/doi.org\/10.3322\/canjclin.53.1.5","journal-title":"CA Cancer J Clin"},{"key":"1303_CR2","first-page":"101","volume":"42","author":"CT Griffiths","year":"1975","unstructured":"Griffiths CT. Surgical resection of Tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101\u20134.","journal-title":"Natl Cancer Inst Monogr"},{"key":"1303_CR3","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","volume":"25","author":"WE Winter 3rd","year":"2007","unstructured":"Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial Ovarian cancer: a gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621\u20137. https:\/\/doi.org\/10.1200\/JCO.2006.10.2517","journal-title":"J Clin Oncol"},{"key":"1303_CR4","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.3390\/jcm10245927","volume":"10","author":"RL Johnson","year":"2021","unstructured":"Johnson RL, Laios A, Jackson D, Nugent D, Orsi NM, Theophilou G, et al. The uncertain benefit of adjuvant chemotherapy in advanced low-grade serous Ovarian cancer and the pivotal role of surgical cytoreduction. J Clin Med. 2021;10:5927. https:\/\/doi.org\/10.3390\/jcm10245927","journal-title":"J Clin Med"},{"key":"1303_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","volume":"103","author":"DS Chi","year":"2006","unstructured":"Chi DS, Eisenhauer EL, Lang J, Huh J, Abu-Rustum NR, Sonoda Y, et al. What is the optimal goal of primary cytoreductive Surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559\u201364. https:\/\/doi.org\/10.1016\/j.ygyno.2006.03.051","journal-title":"Gynecol Oncol"},{"key":"1303_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","volume":"114","author":"DS Chi","year":"2009","unstructured":"Chi DS, Eisenhauer EL, Zivanovic O, Abu-Rustum NR, Levine DA, Guile MW, et al. Improved progression-free and overall survival in advanced Ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26\u201331. https:\/\/doi.org\/10.1016\/j.ygyno.2009.03.018","journal-title":"Gynecol Oncol"},{"key":"1303_CR7","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial Ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour Les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer. 2009;115:1234\u201344. https:\/\/doi.org\/10.1002\/cncr.24149","journal-title":"Cancer"},{"key":"1303_CR8","first-page":"61","volume":"73","author":"FG Lawton","year":"1989","unstructured":"Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking Surgery in advanced, unresected epithelial Ovarian cancer. Obstet Gynecol. 1989;73:61\u20135.","journal-title":"Obstet Gynecol"},{"key":"1303_CR9","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","volume":"103","author":"RE Bristow","year":"2006","unstructured":"Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced Ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103:1070\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2006.06.025","journal-title":"Gynecol Oncol"},{"key":"1303_CR10","doi-asserted-by":"publisher","first-page":"CD005343","DOI":"10.1002\/14651858.CD005343.pub5","volume":"10","author":"SL Coleridge","year":"2019","unstructured":"Coleridge SL, Bryant A, Kehoe S, Morrison J. Chemotherapy versus Surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2019;10:CD005343. https:\/\/doi.org\/10.1002\/14651858.CD005343.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"1303_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ygyno.2004.01.029","volume":"94","author":"DS Chi","year":"2004","unstructured":"Chi DS, Franklin CC, Levine DA, Akserol F, Sabbatini P, Jarnagin WR, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650\u20134. https:\/\/doi.org\/10.1016\/j.ygyno.2004.01.029","journal-title":"Gynecol Oncol"},{"key":"1303_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/s0090-8258(03)00278-6","volume":"90","author":"SM Eisenkop","year":"2003","unstructured":"Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of Tumor volume before Surgery and the cytoreductive outcome on survival for patients with advanced Ovarian cancer: a prospective study. Gynecol Oncol. 2003;90:390\u20136. https:\/\/doi.org\/10.1016\/s0090-8258(03)00278-6","journal-title":"Gynecol Oncol"},{"key":"1303_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ygyno.2013.08.007","volume":"131","author":"DP Barton","year":"2013","unstructured":"Barton DP, Adib T, Butler J. Surgical practice of UK gynaecological oncologists in the treatment of primary advanced epithelial Ovarian cancer (PAEOC): a questionnaire survey. Gynecol Oncol. 2013;131:347\u201351. https:\/\/doi.org\/10.1016\/j.ygyno.2013.08.007","journal-title":"Gynecol Oncol"},{"key":"1303_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/ijgc-2020-001248","volume":"30","author":"C Fotopoulou","year":"2020","unstructured":"Fotopoulou C, Concin N, Planchamp F, Chiva L, Cina A, Ergonol O, et al. Quality indicators for advanced Ovarian cancer Surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int J Gynecol Cancer. 2020;30:436\u201340. https:\/\/doi.org\/10.1136\/ijgc-2020-001248","journal-title":"Int J Gynecol Cancer"},{"key":"1303_CR15","doi-asserted-by":"publisher","first-page":"107327482110446","DOI":"10.1177\/10732748211044678","volume":"28","author":"A Laios","year":"2021","unstructured":"Laios A, Katsenou A, Tan YS, Johnson R, Otify M, Kaufmann A, et al. Feature selection is critical for 2-year prognosis in advanced stage high grade serous Ovarian cancer by using machine learning. Cancer Control. 2021;28:10732748211044678. https:\/\/doi.org\/10.1177\/10732748211044678","journal-title":"Cancer Control"},{"key":"1303_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of Surgical Complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae","journal-title":"Ann Surg"},{"key":"1303_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ygyno.2014.04.013","volume":"133","author":"DG Mutch","year":"2014","unstructured":"Mutch DG, Prat J. FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133:401\u20134. https:\/\/doi.org\/10.1016\/j.ygyno.2014.04.013","journal-title":"Gynecol Oncol"},{"key":"1303_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.compbiomed.2011.04.014","volume":"41","author":"AC Newsham","year":"2011","unstructured":"Newsham AC, Johnston C, Hall G, Leahy MG, Smith MB, Vikram A, et al. Development of an advanced database for clinical trials integrated with an electronic patient record system. Comput Biol Med. 2011;41:575\u201386. https:\/\/doi.org\/10.1016\/j.compbiomed.2011.04.014","journal-title":"Comput Biol Med"},{"key":"1303_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"1303_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/ijgc-2019-000356","volume":"29","author":"G Nelson","year":"2019","unstructured":"Nelson G, Bakkum-Gamez J, Kalogera E, Glaser G, Altman A, Meyer LA, et al. Guidelines for perioperative care in gynecologic\/oncology: enhanced recovery after Surgery (ERAS) society recommendations-2019 update. Int J Gynecol Cancer. 2019;29:651\u201368. https:\/\/doi.org\/10.1136\/ijgc-2019-000356","journal-title":"Int J Gynecol Cancer"},{"key":"1303_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/bja\/aev454","volume":"116","author":"J Moran","year":"2016","unstructured":"Moran J, Wilson F, Guinan E, McCormick P, Hussey J, Moriarty J. Role of cardiopulmonary exercise testing as a risk assessment method in patients undergoing intra-abdominal Surgery: a systematic review. Br J Anaesth. 2016;116:177\u201391. https:\/\/doi.org\/10.1093\/bja\/aev454","journal-title":"Br J Anaesth"},{"key":"1303_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/jcm11010087","volume":"11","author":"A Laios","year":"2022","unstructured":"Laios A, De Oliveira Silva RV, Dantas De Freitas DL, Tan YS, Saalmink G, Zubayraeva A, et al. Machine learning-based risk prediction of critical care unit admission for Advanced Stage High Grade Serous Ovarian Cancer patients undergoing cytoreductive Surgery: the Leeds-Natal score. J Clin Med. 2022;11:87. https:\/\/doi.org\/10.3390\/jcm11010087","journal-title":"J Clin Med"},{"key":"1303_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ygyno.2008.07.022","volume":"111","author":"M H\u00f6ckel","year":"2008","unstructured":"H\u00f6ckel M. Laterally extended endopelvic resection (LEER)--principles and practice. Gynecol Oncol. 2008;111:13\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2008.07.022","journal-title":"Gynecol Oncol"},{"key":"1303_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF02524342","volume":"11","author":"MJ Lopez","year":"2004","unstructured":"Lopez MJ, Luna-P\u00e9rez P. Composite pelvic exenteration: is it worthwhile? Ann Surg Oncol. 2004;11:27\u201333. https:\/\/doi.org\/10.1007\/BF02524342","journal-title":"Ann Surg Oncol"},{"key":"1303_CR25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/ijgc-2021-002951","volume":"31","author":"C Fotopoulou","year":"2021","unstructured":"Fotopoulou C, Planchamp F, Aytulu T, Chiva L, Cina A, Erg\u00f6n\u00fcl \u00d6, et al. European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced Ovarian cancer patients undergoing debulking Surgery. Int J Gynecol Cancer. 2021;31:1199\u2013206. https:\/\/doi.org\/10.1136\/ijgc-2021-002951","journal-title":"Int J Gynecol Cancer"},{"key":"1303_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/jpm12040607","volume":"12","author":"A Laios","year":"2022","unstructured":"Laios A, Kalampokis E, Johnson R, Thangavelu A, Tarabanis C, Nugent D, et al. Explainable Artificial Intelligence for Prediction of Complete Surgical Cytoreduction in Advanced-Stage Epithelial Ovarian Cancer. J Pers Med. 2022;12:607. https:\/\/doi.org\/10.3390\/jpm12040607","journal-title":"J Pers Med"},{"key":"1303_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/ejso.2000.1038","volume":"27","author":"PH Sugarbaker","year":"2001","unstructured":"Sugarbaker PH. Cytoreductive Surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol. 2001;27:239\u201343. https:\/\/doi.org\/10.1053\/ejso.2000.1038","journal-title":"Eur J Surg Oncol"},{"key":"1303_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ygyno.2007.05.032","volume":"107","author":"GD Aletti","year":"2007","unstructured":"Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for Ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107:99\u2013106. https:\/\/doi.org\/10.1016\/j.ygyno.2007.05.032","journal-title":"Gynecol Oncol"},{"key":"1303_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23","journal-title":"Cancer Treat Res"},{"key":"1303_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ygyno.2011.04.041","volume":"122","author":"CA Hamilton","year":"2011","unstructured":"Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR, et al. The impact of Disease distribution on survival in patients with stage III epithelial Ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122:521\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2011.04.041","journal-title":"Gynecol Oncol"},{"key":"1303_CR31","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","volume":"30","author":"A Fagotti","year":"2020","unstructured":"Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. Randomized trial of primary debulking Surgery versus neoadjuvant chemotherapy for advanced epithelial Ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30:1657\u201364. https:\/\/doi.org\/10.1136\/ijgc-2020-001640","journal-title":"Int J Gynecol Cancer"},{"key":"1303_CR32","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ygyno.2015.12.004","volume":"140","author":"H Soleymani Majd","year":"2016","unstructured":"Soleymani Majd H, Ferrari F, Manek S, Gubbala K, Campanile RG, Hardern K, et al. Diaphragmatic peritonectomy vs. full thickness resection with pleurectomy during visceral-peritoneal debulking (VPD) in 100 consecutive patients with stage IIIC-IV Ovarian cancer: a surgical-histological analysis. Gynecol Oncol. 2016;140:430\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2015.12.004","journal-title":"Gynecol Oncol"},{"key":"1303_CR33","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3390\/cancers15030966","volume":"15","author":"A Laios","year":"2023","unstructured":"Laios A, Kalampokis E, Johnson R, Munot S, Thangavelu A, Hutson R, et al. Development of a novel intra-operative score to record Diseases\u2019 anatomic fingerprints (ANAFI score) for the prediction of complete cytoreduction in Advanced-Stage Ovarian Cancer by using machine learning and explainable Artificial Intelligence. Cancers (Basel). 2023;15:966. https:\/\/doi.org\/10.3390\/cancers15030966","journal-title":"Cancers (Basel)"},{"key":"1303_CR34","doi-asserted-by":"publisher","first-page":"676e1","DOI":"10.1016\/j.ajog.2007.10.495","volume":"197","author":"GD Aletti","year":"2007","unstructured":"Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary Surgery for advanced Ovarian cancer. Am J Obstet Gynecol. 2007;197:676e1\u20137. https:\/\/doi.org\/10.1016\/j.ajog.2007.10.495","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 3","key":"1303_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S0959-8049(11)70152-6","volume":"47","author":"I Vergote","year":"2011","unstructured":"Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary Surgery or neoadjuvant chemotherapy followed by interval debulking Surgery in advanced Ovarian cancer. Eur J Cancer. 2011;47(Suppl 3):88\u201392. https:\/\/doi.org\/10.1016\/S0959-8049(11)70152-6","journal-title":"Eur J Cancer"},{"key":"1303_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/CCO.0000000000000387","volume":"29","author":"FA Eggink","year":"2017","unstructured":"Eggink FA, Koopmans CM, Nijman HW. Surgery for patients with newly diagnosed advanced Ovarian cancer: which patient, when and extent? Curr Opin Oncol. 2017;29:351\u20138. https:\/\/doi.org\/10.1097\/CCO.0000000000000387","journal-title":"Curr Opin Oncol"},{"key":"1303_CR37","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000113051","volume":"72","author":"D de Jong","year":"2007","unstructured":"de Jong D, Eijkemans MJ, Lie Fong S, Gerestein CG, Kooi GS, Baalbergen A, et al. Preoperative predictors for residual Tumor after Surgery in patients with ovarian carcinoma. Oncology. 2007;72:293\u2013301. https:\/\/doi.org\/10.1159\/000113051","journal-title":"Oncology"},{"key":"1303_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13048-020-00700-0","volume":"13","author":"A Laios","year":"2020","unstructured":"Laios A, Gryparis A, de Jong D, Hutson R, Theophilou G, Leach C. Predicting complete cytoreduction for advanced Ovarian cancer patients using nearest-neighbor models. J Ovarian Res. 2020;13:117. https:\/\/doi.org\/10.1186\/s13048-020-00700-0","journal-title":"J Ovarian Res"},{"key":"1303_CR39","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive Surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248\u201359. https:\/\/doi.org\/10.1200\/JCO.2002.20.5.1248","journal-title":"J Clin Oncol"},{"key":"1303_CR40","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00268-019-04950-y","volume":"43","author":"MJ Hughes","year":"2019","unstructured":"Hughes MJ, Hackney RJ, Lamb PJ, Wigmore SJ, Deans DAC, Skipworth RJE. Prehabilitation before Major Abdominal Surgery: a systematic review and Meta-analysis. World J Surg. 2019;43:1661\u20138. https:\/\/doi.org\/10.1007\/s00268-019-04950-y","journal-title":"World J Surg"},{"key":"1303_CR41","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1245\/s10434-020-09494-3","volume":"28","author":"KM Mulligan","year":"2021","unstructured":"Mulligan KM, Glennon K, Donohoe F, O\u2019Brien Y, Mc Donnell BC, Bartels HC, et al. Multidisciplinary Surgical Approach to increase complete cytoreduction rates for Advanced Ovarian Cancer in a Tertiary Gynecologic Oncology Center. Ann Surg Oncol. 2021;28:4553\u201360. https:\/\/doi.org\/10.1245\/s10434-020-09494-3","journal-title":"Ann Surg Oncol"},{"key":"1303_CR42","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ygyno.2018.06.008","volume":"150","author":"MS Ross","year":"2018","unstructured":"Ross MS, Burriss ME, Winger DG, Edwards RP, Courtney-Brooks M, Boisen MM. Unplanned postoperative intensive care unit admission for Ovarian cancer cytoreduction is associated with significant decrease in overall survival. Gynecol Oncol. 2018;150:306\u201310. 0.1016\/j.ygyno.2018.06.008.","journal-title":"Gynecol Oncol"},{"key":"1303_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2010.05.031","volume":"119","author":"DS Chi","year":"2010","unstructured":"Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, et al. The incidence of major Complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol. 2010;119:38\u201342. https:\/\/doi.org\/10.1016\/j.ygyno.2010.05.031","journal-title":"Gynecol Oncol"},{"key":"1303_CR44","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.ejso.2018.05.001","volume":"44","author":"S Nazzani","year":"2018","unstructured":"Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Shariat SF, et al. In-hospital length of stay after major surgical oncological procedures. Eur J Surg Oncol. 2018;44:969\u201374. https:\/\/doi.org\/10.1016\/j.ejso.2018.05.001","journal-title":"Eur J Surg Oncol"},{"key":"1303_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ygyno.2020.04.048","volume":"158","author":"G Searle","year":"2020","unstructured":"Searle G, Pounds R, Phillips A, Kehoe A, Balega J, Singh K, et al. Prolonged interruption of chemotherapy in patients undergoing delayed debulking Surgery for advanced high grade serous Ovarian cancer is associated with a worse prognosis. Gynecol Oncol. 2020;158:54\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2020.04.048","journal-title":"Gynecol Oncol"},{"key":"1303_CR46","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/01.sla.0000118753.22830.41","volume":"239","author":"C Vincent","year":"2004","unstructured":"Vincent C, Moorthy K, Sarker SK, Chang A, Darzi AW. Systems approaches to surgical quality and safety: from concept to measurement. Ann Surg. 2004;239:475\u201382. https:\/\/doi.org\/10.1097\/01.sla.0000118753.22830.41","journal-title":"Ann Surg"},{"key":"1303_CR47","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3390\/cancers13071593","volume":"13","author":"M Alejandra","year":"2021","unstructured":"Alejandra M, Gertych W, Pomel C, Ferron G, Lusque A, Angeles MA, et al. Adherence to French and ESGO Quality indicators in Ovarian Cancer Surgery: an Ad-Hoc analysis from the prospective Multicentric CURSOC Study. Cancers. 2021;13:1593. https:\/\/doi.org\/10.3390\/cancers13071593","journal-title":"Cancers"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-023-01303-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-023-01303-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-023-01303-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T20:02:47Z","timestamp":1699732967000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-023-01303-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1303"],"URL":"https:\/\/doi.org\/10.1186\/s13048-023-01303-1","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"26 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}